2020
DOI: 10.1016/j.ijpharm.2020.119382
|View full text |Cite
|
Sign up to set email alerts
|

The development and validation of a quality by design based process analytical tool for the inline quantification of Ramipril during hot-melt extrusion

Abstract: The development and validation of a quality by design based process analytical tool for the inline quantification of Ramipril during hot-melt extrusion

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

1
15
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 21 publications
(17 citation statements)
references
References 29 publications
(39 reference statements)
1
15
0
Order By: Relevance
“…In our previous work, we confirmed the feasibility of utilising HME as a continuous processing platform for the manufacture of FDCs for the management of chronic diseases (Andrews et al, 2019b;Kelleher et al, 2018). Additionally, we demonstrated the suitability of Raman spectroscopy for the inline quantification of Ramipril during processing by utilising the quality by design approach and PAT framework (Andrews et al, 2019a;Dadou et al, 2020b).…”
Section: Introductionsupporting
confidence: 63%
See 2 more Smart Citations
“…In our previous work, we confirmed the feasibility of utilising HME as a continuous processing platform for the manufacture of FDCs for the management of chronic diseases (Andrews et al, 2019b;Kelleher et al, 2018). Additionally, we demonstrated the suitability of Raman spectroscopy for the inline quantification of Ramipril during processing by utilising the quality by design approach and PAT framework (Andrews et al, 2019a;Dadou et al, 2020b).…”
Section: Introductionsupporting
confidence: 63%
“…Nevertheless, HME has not been widely implemented as a means of routine oral dose manufacture in the pharmaceutical industry. Major challenges include regulatory uncertainty towards such manufacturing platforms, and the need to reconsider the infrastructure of companies to accommodate the emerging view of advanced manufacturing technologies (Dadou et al, 2020b;Lee, 2017).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…This field of cross-disciplinary research between advanced therapeutics, computational tools and manufacturing technologies under the umbrella of QbD based digital frameworks will ultimately transform the amorphous formulation design and process into a new field of predictive science. Subsequently, we believe that the specific knowledge and expertise will be combined to develop reliable amorphous formulation and process design tools for quality and rapid realisation of advanced therapies in the foreseeable future (Dadou et al, 2020). Therefore, the development of digital framework based on both thermodynamic and kinetic principles for drugpolymer combinations integrated with specific manufacturing techniques will be vital for this industry.…”
Section: Introductionmentioning
confidence: 99%
“…Hot melt extrusion (HME) is increasingly applied in the pharmaceutical industry, mostly for solubilization of poorly soluble active pharmaceutical ingredients ( McFall et al 2019 ; Monschke et al 2020 ; Schittny et al 2018 ; Steffens and Wagner 2020 ; Vasoya et al 2019 ) (APIs) in immediate release, control release ( Fukuda et al 2006 ; Vo et al 2016 ; Zhu et al 2006 ) and nano ( Baumgartner et al, 2016 , Baumgartner et al, 2014 ; Bhagurkar et al 2017 ; Patil et al 2015 ; Silva et al 2018 ) formulations, as well as for the manufacturing of specific drug delivery devices ( Bode et al 2019 ; Cossé et al 2017 ; Eder et al 2017 ; Koutsamanis et al 2019 ). This trend calls for fast, reliable and inexpensive product and process development ( Breitenbach 2002 ; Crowley et al 2007 ; Dadou et al 2020 ; Evans et al 2018 ; Huang et al 2017 ; Kohlgrüber 2007 ; Matić et al 2020 ; Patil et al 2016 ; Rauwendaal 2014 ; Repka et al 2007 ; Saerens et al 2013 ). Typically, formulation and process development are disconnected, i.e., during the formulation development the formulation's processability is not considered.…”
Section: Introductionmentioning
confidence: 99%